Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers

机译：布鲁顿酪氨酸激酶（Btk）抑制剂依鲁替尼对糖尿病足溃疡大鼠模型的影响及其机制

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

BackgroundDiabetes causes damage to the soft tissue and bone structure of the foot, referred to as “diabetic foot”. Ibrutinib is a Bruton tyrosine kinase (Btk) inhibitor, and the role and mechanism of ibrutinib on the diabetic foot have not been elucidated.

机译：背景技术糖尿病会损害被称为“糖尿病足”的脚的软组织和骨骼结构。依鲁替尼是一种Bruton酪氨酸激酶（Btk）抑制剂，尚未阐明依鲁替尼在糖尿病足中的作用和机制。

著录项

期刊名称 Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
作者
Xuedong Yang; Zhenhao Cao; Peigang Wu; Zhong Li;
展开▼
作者单位

展开▼
年(卷),期 2019(25),-1
年度 2019
页码 7951–7957
总页数 7
原文格式 PDF
正文语种
中图分类
关键词
Inflammation Rage Vascular Endothelial Growth Factor A;

机译：炎症;愤怒;血管内皮生长因子A;

相似文献

外文文献
中文文献
专利

1. Antiarthritis effect of a novel Bruton's tyrosine kinase (BTK) inhibitor in rat collagen-induced arthritis and mechanism-based pharmacokinetic/pharmacodynamic modeling: relationships between inhibition of BTK phosphorylation and efficacy. [J] . Liu L, Di Paolo J, Barbosa J, The Journal of Pharmacology and Experimental Therapeutics: Official Publication of the American Society for Pharmacology and Experimental Therapeutics . 2011,第1期

机译：新型Bruton酪氨酸激酶（BTK）抑制剂在大鼠胶原诱导的关节炎中的抗关节炎作用和基于机理的药代动力学/药效学模型：抑制BTK磷酸化与功效之间的关系。
2. Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer [J] . Zhen Zhu, Lanlan Ling, Lezhong Qi, OncoTargets and therapy . 2020,第2期

机译：Bruton的酪氨酸激酶（BTK）抑制剂（Ibrutinib） - 抑制的迁移和侵袭前列腺癌
3. Ibrutinib significantly inhibited Bruton's tyrosine kinase (BTK) phosphorylation, in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model [J] . Yaya Chu, Sanghoon Lee, Tishi Shah, Oncoimmunology. . 2019,第1期

机译：Ibrutinib显着抑制了Bruton的酪氨酸激酶（BTK）磷酸化，体外增殖，并在临床前Burkitt淋巴瘤（BL）模型中提高了整体存活
4. CNX-774, an Irreversible, Selective and Orally Bioavailable Inhibitor of Bruton's Tyrosine Kinase: In Vitro ADME, Selectivity, and Pharmacokinetic Properties [C] . Prasoon Chaturvedi, Matthew Labenski, Erica Evans, American Society for Mass Spectrometry Conference on Mass Spectrometry and Allied Topics . 2011

机译：CNX-774，Bruton的酪氨酸激酶的不可逆转，选择性和口服生物可利用的抑制剂：体外Adme，选择性和药代动力学性能
5. An RNAi screen targeting the protein tyrosine kinases identifies Bruton's tyrosine kinase (BTK) as a breast cancer cell survival factor. [D] . Eifert, Cheryl. 2009

机译：靶向蛋白质酪氨酸激酶的RNAi筛选可将布鲁顿酪氨酸激酶（BTK）识别为乳腺癌细胞生存因子。
6. Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer [O] . Zhen Zhu, Lanlan Ling, Lezhong Qi, 2020

机译：布鲁顿的酪氨酸激酶（BTK）抑制剂（依鲁替尼）-抑制了前列腺癌的迁移和侵袭
7. >Bruton’s Tyrosine Kinase (BTK) Inhibitor (Ibrutinib)-Suppressed Migration and Invasion of Prostate Cancer [O] . Zhen Zhu, Lanlan Ling, Lezhong Qi, 2020

机译：> Bruton的酪氨酸激酶（BTK）抑制剂（伊布勒替尼） - 抑制的迁移和前列腺癌的侵袭

Effect and Mechanism of the Bruton Tyrosine Kinase (Btk) Inhibitor Ibrutinib on Rat Model of Diabetic Foot Ulcers

摘要

著录项

相似文献

相关主题

期刊订阅